Your session is about to expire
← Back to Search
PCSK9 inhibitor for Type 2 Diabetes (CHORD Trial)
CHORD Trial Summary
This trial is investigating the difference in heart disease risk factors for those with type 2 diabetes and those without the condition. Cholesterol-lowering medication will be given to participants in order to better understand how diabetes contributes to an increased risk for heart disease and stroke, even after cholesterol is reduced.
- Type 2 Diabetes
CHORD Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.CHORD Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You must be between 18 and 90 years old.Your LDL cholesterol level is higher than 100mg/dl.You can and want to sign a paper saying you agree to be in the study.Your cholesterol levels are too high.
- Group 1: Type 2 Diabetes group
- Group 2: Control group
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any available slots for new participants in this research?
"That is correct. The listing on clinicaltrials.gov tells us that the trial coordinators are still looking for eligible candidates. The first posting was on June 22nd, 2020 with the most recent update being January 14th, 2022. They hope to have 150 enrollees from 1 location."
Is this a groundbreaking clinical trial?
"There have been a total of 104 clinical trials for PCSK9 inhibitors that are still active as of now. These trials are located in 354 cities across 45 countries and the first one dates back to 2005. This initial trial, sponsored by Merck Sharp & Dohme LLC, had 80 participants and completed its Phase 4 drug approval stage. In the 16 years since then, 661 similar studies have been completed."
How many individuals are being recruited for this research project?
"That is correct. The clinicaltrials.gov website shows that this trial is still looking for participants. The first posting was on June 22nd 2020 and the most recent update was January 14th 2022. So far, 1 site has enrolled 150 people."
Could I qualify to be a part of this research project?
"This trial is open to adults with type 2 diabetes mellitus between the ages of 18 and 89. To date, 150 patients have been enrolled in this clinical study."
For what medical conditions is PCSK9 inhibitor typically prescribed?
"A PCSK9 inhibitor is a medication that is most frequently used to lower lipid levels. However, it can also be effective in treating lipidemias, postoperative thromboembolism, and anginal pain."
Do elderly citizens qualify for this clinical trial?
"In order to meet the requirements for this trial, applicants must be aged 18-89. Out of the many clinical trials available, 206 are specifically designed for children and 1262 cater to older adults."
Are there other examples in the medical literature of a PCSK9 inhibitor being used?
"There are a total of 104 ongoing studies related to PCSK9 inhibitors. Of these, 24 are Phase 3 clinical trials. Many of the research centres for this topic are based in Omaha, Nebraska; though, there are 1,405 locations across the globe conducting similar investigations."
Share this study with friends
Copy Link
Messenger